SS-31

Overview

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin in the inner mitochondrial membrane to stabilize cristae architecture and optimize electron transport chain efficiency without increasing mitochondrial biogenesis. Mitochondrial membrane repair and cardiolipin stabilization for organ protection (kidney, heart, brain), pre-surgical optimization, and redox homeostasis restoration in aging and metabolic stress.

SS-31 was developed in the 2000s by Dr. Hazel H. Szeto at Weill Cornell Medicine and Stealth BioTherapeutics as a targeted mitochondrial therapeutic. The peptide emerged from research into cardiolipin biology—the unique dimeric phospholipid that provides the structural scaffolding for respiratory complexes in the inner mitochondrial membrane. Early development focused on heart failure (TAME-HF trial, 2019), which failed to meet primary endpoints for exercise capacity, but the compound demonstrated sufficient safety and mechanistic validation to secure FDA accelerated approval in September 2025 for Barth syndrome, a rare life-threatening cardiolipin remodeling disorder characterized by severe fatigue and cardiac dysfunction.

Community adoption began as early as 2014 on LongeCity forums, where users sought sequence verification (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) for DIY compounding before commercial availability. Adoption accelerated following in-vitro studies showing MitoQ caused mitochondrial swelling and depolarization in kidney tissue while SS-31 did not, prompting a community migration toward SS-31 as the safer mitochondrial antioxidant. The compound occupies a distinct niche in biohacking protocols as the only available agent that directly targets cardiolipin to repair "hardware" (membrane structure) rather than stimulating "software" (biogenesis).

Current status reflects tension between clinical validation and accessibility. While Phase 2 trials showed functional benefits in heart failure (improved 6-minute walk distance) and the TAZPOWER extension studies demonstrated durable improvements in fatigue and muscle strength in Barth syndrome, the TAME-HF failure limited pharmaceutical investment. Community use persists based on mechanistic rationale—cardiolipin stabilization, cristae restoration, and redox optimization—despite costs often exceeding $400-1000 monthly for clinical-equivalent dosing (40mg/day).

Observed Effects

Primary Intended Effects (Clinical) In aged C57BL/6Nia mice (26 months), 8 weeks of 3mg/kg/day SS-31 restored gastrocnemius mitochondrial ATPmax and P/O coupling to young control levels, increased muscle mass, and significantly improved treadmill endurance versus aged controls (in vivo 31P MRS and optical spectroscopy). In human renal revascularization procedures, SS-31 patients suffered only a 6% drop in kidney oxygen levels 24 hours post-procedure versus 47% in placebo; at three months, the SS-31 cohort showed 30% greater renal blood flow and 11% improved kidney function compared to placebo decline.

In C26 colon adenocarcinoma cachexia mice, SS-31 normalized cardiolipin fatty acid alterations, rescued intracellular ATP and succinate dehydrogenase activity, and prevented glycolytic myofiber atrophy—though efficacy became refractory by day 28 despite dose escalation. In bleomycin-induced pulmonary fibrosis, 5mg/kg IP daily for 28 days preserved mitochondrial structure and ATP, reduced TNF-α, IL-1β, and IL-6, and attenuated fibrosis index. Human ex vivo studies (Type 2 Diabetes, n=61) demonstrated reduced ROS, decreased ER stress markers (GRP78, CHOP), and improved leukocyte-endothelium interactions versus inactive analog SS-20.

Secondary and Community-Reported Effects Users report employing SS-31 for energy support during GLP-1 agonist-induced caloric restriction (900-1500 kcal/day), pre-surgical optimization (5-10mg daily for 2 weeks pre-op), and recovery from environmental toxin exposure. Practitioners note improved surgical recovery outcomes when patients present with "mitochondrially happy" status pre-operatively. Some users report enhanced cognitive clarity on high-demand work days using nasal spray administration, though subjective energy effects vary significantly between individuals.

Distinguishing Clinical from Community Data Clinical effects emphasize objective biomarkers (ATPmax, renal blood flow, ejection fraction improvements in diabetic cardiomyopathy at 2.5mg/kg/day in mice). Community reports focus on subjective vitality, exercise tolerance, and fatigue management, with frequent null results in short-term (2-week) trials among healthy users. The disconnect between robust preclinical efficacy and variable subjective response drives community experimentation with dosing (500mcg to 50mg) and sequencing protocols.

Adverse Effects

Commonly Reported Injection site reactions dominate community reports: painless subcutaneous nodules (particularly when stacked with NAD+), redness, swelling, itching, and mechanical irritation. GI upset, gas, dizziness, and headache occur in a minority of users. MOTS-c produces more injection "sting" than SS-31 in comparative user reports.

Rarely Reported Serious allergic reactions requiring discontinuation: fast/erratic heartbeat, profuse sweating, shortness of breath, confusion, severe weakness, loss of coordination, stiff muscles, high fever, or ocular symptoms (blurred vision, tunnel vision, eye pain, swelling, halos). Excessive fatigue and severe headaches warrant cessation.

Theoretical/Not Reported Alex Kikel warns that extreme dosing may cause "over-spinning" of electrons in the ETC, potentially reversing benefits through excessive electron management—though this remains mechanistic speculation. Cytochrome c leakage and apoptosis risks are theoretical concerns if administered to patients with severely damaged mitochondria, based on mechanistic understanding rather than documented cases. No significant organ toxicity or mortality reported in clinical trials (Barth syndrome, heart failure) at doses up to 40mg daily for 24 weeks.

Mitochondrial membrane repair via cardiolipin stabilization and cristae restoration, improving ATP production efficiency without requiring biogenesis.

Dosing Protocols

Standard Clinical Protocol FDA-approved Barth syndrome dosing and Phase 2 heart failure trials (PROGRESS): 40mg subcutaneous daily, with some protocols extending 24 weeks without observed desensitization. TAZPOWER extension studies used similar dosing with durable improvements in fatigue and 6-minute walk distance.

Community Standard (Cost-Constrained) Due to expense ($100-200 per 10mg vial), community protocols typically employ 1-5mg daily, with 500mcg-2mg representing maintenance or conservative approaches. Jay Campbell recommends 500mcg subcutaneous morning, 5 days per week, for 8-week cycles. Alex Kikel suggests starting at 200-500mcg upon waking for one week before escalating.

Aggressive/Therapeutic Protocols Athletic or organ-targeted protocols use 10-20mg daily. Dr. Adeel Khan uses 5-10mg daily for 2 weeks pre-surgery. Alex Kikel reports therapeutic IV dosing of 20-50mg daily for chronic kidney disease (EGFR improvements from 16 to 47 to 72 documented), and 100mg IV for neuroregeneration after parasite-induced brain damage. High-dose protocols require splitting injections (>60 units or 0.6mL) into two subcutaneous sites or using intramuscular route for volumes >1mL.

Titration Strategy Alex Kikel describes linear dose-response. Users micro-titrate from 250-500mcg to find individual tolerance, with some reporting 3mg too much (overstimulation) requiring reduction to 2.5mg. Typical escalation: 1mg → 2mg → 3mg → 5mg in weekly increments.

Cycling Standard: 8-12 weeks on, 4-8 weeks off to reassess mitochondrial biomarkers (lactate:pyruvate ratio, 6-minute walk test). Alternative: 4 weeks on, 2 weeks off repeating pattern. Weekend-only protocols (Saturday/Sunday) target electron-level healing without daily cost burden.

Reconstitution and Administration Reconstitute lyophilized powder with bacteriostatic water (BAC) via slow injection down vial wall; gentle swirling (no vigorous shaking). Concentrations vary by preference: 20mg/mL (0.5mL BAC per 10mg) for low-volume injection versus 10mg/mL (1mL BAC per 10mg) for easier measurement. 2mg/mL (5mL BAC per 10mg) used for high-dose protocols requiring volume splitting. Administer subcutaneous (abdomen/thigh) or intramuscular; morning fasted state most common; pre-workout timing optional. IV administration requires slow push technique and is reserved for clinical/therapeutic settings.

Storage Lyophilized: -20°C freezer. Reconstituted: 2-8°C refrigerator, use within 4-6 weeks (sources conflict on exact stability window). Protect from light; SS-31 exhibits charge-sensitive stability requiring stricter protocols than typical peptides.

Protocols by Goal

Metabolic Health / GLP-1 Fatigue For users experiencing fatigue during semaglutide, tirzepatide, or retatrutide-induced caloric restriction (900-1500 kcal/day): 5mg daily subcutaneous for 8-12 weeks to support mitochondrial capacity under energetic stress. Stack with injectable L-carnitine (fatty acid transport) and 5-Amino-1MQ (NAD+ preservation). Biomarker target: stable energy levels, maintained exercise tolerance despite caloric deficit.

Pre-Surgical Optimization Dr. Adeel Khan protocol: 5-10mg daily for 2 weeks pre-operatively. Rationale: low oxidative stress and optimized ATP production improve recovery from procedures involving stem cells, transfusions, or extensive tissue manipulation. Particularly indicated for patients with low baseline mitochondrial function.

Longevity / Anti-Aging Conservative: 1-5mg daily 5 days/week (weekdays) for 8-12 weeks, 8 weeks off. Weekend protocol: 5-10mg Saturday and Sunday only with immediate 5-10 minute red/NIR light exposure post-injection to drive biogenesis. Stack with Urolithin A (500mg daily) for mitochondrial recycling. Biomarkers: lactate:pyruvate ratio, 6-minute walk test, Generation Lab cellular aging test (biological noise measurement).

Organ Repair (CKD, Heart Failure) Therapeutic dosing: 20-50mg IV daily (requires medical supervision) or 40mg subcutaneous daily (clinical trial dose). Target: EGFR improvement (CKD), BNP/NT-proBNP reduction (cardiac), 6-minute walk distance. Duration: 12-24 weeks with monitoring. Alex Kikel reports EGFR recovery from 16 to 72 over treatment course in kidney disease.

Performance / Body Composition Generally considered inferior to MOTS-c or SLU-PP-332 for direct performance enhancement. If used: 4-5mg daily as primer before MOTS-c cycles, or 10mg daily for 20 days followed by MOTS-c transition. Not recommended as standalone ergogenic aid.

Neurological / Cognitive Support Nasal spray formulation (compounded) for high cognitive demand days: 1-5mg administered intranasally to target neural tissue specifically. Alex Kikel recommends this over injectable for big work days requiring neurological recovery rather than physical performance. Systemic injection (IM/subQ) used for general brain health support.

Common Stacks

Similar Compounds

Community Context

SS-31 circulates primarily within advanced longevity communities (LongeCity since 2014), biohacking practitioners, and GLP-1 user forums. Adoption accelerated after September 2025 FDA approval for Barth syndrome (brand Forzinity), which provided regulatory validation for the cardiolipin-targeting mechanism despite earlier TAME-HF trial failures in heart failure. The compound occupies a unique position as the only available structural mechanic for mitochondria versus software biogenesis agents like MOTS-c.

Cost fundamentally shapes community usage patterns. SS-31 forces dosing compromises (500mcg-2mg instead of clinical 40mg), vial mathematics (using 10mg vials for 2.5 doses), and food budget reallocation. This drives group buy arrangements and vendor affiliate networks to reduce costs.

Community reputation emphasizes safety and tolerability over dramatic subjective effects. Users migrated from MitoQ due to kidney safety concerns, and SS-31 is considered safer at high doses than BPC-157 (hypotension risk) or MOTS-c (injection sting/adverse reactions). However, it is widely viewed as inferior to MOTS-c for cardiovascular fitness and to SLU-PP-332 for metabolic performance. The consensus: SS-31 is a health intervention for organ protection and mitochondrial repair, not a performance enhancer for healthy athletes.

Sourcing remains challenging compared to abundant MOTS-c availability. Sequence verification (D-Arg-Dmt-Lys-Phe-NH2) and purity concerns drive preference for established suppliers.

Community Experience

What Works Pre-surgical priming (5-10mg for 2 weeks) shows consistent reports of improved recovery and reduced complications. Sequential stacking—SS-31 alone for 4 weeks, then overlapping with MOTS-c for 2-4 weeks before discontinuing SS-31—resolves the template problem of biogenesis on damaged mitochondria. Low-dose titration (starting 250-500mcg) identifies individual tolerance thresholds (some users find 3mg overstimulating, requiring 2.5mg sweet spot). Weekend cycling (Sat/Sun only) with immediate light exposure provides sustainable maintenance without daily cost burden.

What Doesn't Short-term trials (1-2 weeks) at standard doses (5mg) frequently produce null subjective results in healthy users. Concurrent administration with MOTS-c or NAD+ may mask individual effects, making it difficult to attribute benefits. Expecting immediate performance enhancement leads to disappointment; SS-31 is protective/healing rather than ergogenic.

Common Mistakes Skipping the priming phase and starting MOTS-c immediately, potentially wasting the biogenesis stimulus on structurally compromised mitochondria. Dosing based on vial consumption convenience rather than pharmacological targets. Expecting visible blood biomarker changes in 4-6 weeks; mitochondrial biogenesis percentage improvements require longer cycles or imaging to verify. Discontinuing due to cost before reaching therapeutic thresholds (20-40mg) for organ repair goals.

How Experienced Users Refine Protocols Practitioners implement 6-month rotation testing: 4-8 weeks MOTS-c, 4-8 weeks SS-31, 4-8 weeks SLU-PP-332, then review notes to identify individual best responder based on body composition, energy, and health markers. Users track injection site reactions to determine IM vs SubQ preference and dilution requirements. Advanced users employ IV administration for organ failure (CKD reversal) or neuroregeneration, though this requires medical supervision. Most experienced users settle on SS-31 as a periodic healing rotation rather than daily staple.

Practical Considerations

Sourcing and Purity FDA-approved Forzinity (40mg) available for Barth syndrome patients via prescription. Research chemical sourcing dominates community use; PeptideSciences and similar vendors supply 10mg, 30mg, and 50mg vials. Group buys reduce cost for 40mg-equivalent dosing. Verify sequence D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2',6'-dimethyltyrosine) and request HPLC purity reports. Storage: lyophilized powder at -20°C stable for months; reconstituted solution at 2-8°C, use within 4-6 weeks.

Reconstitution Technique Slowly inject bacteriostatic water down vial wall (not directly onto powder) to prevent foaming. Gently swirl until dissolved; never shake vigorously. Label with date and concentration immediately. Light-sensitive; store vial in dark or wrapped in foil.

Biomarkers to Track Baseline and follow-up: CBC, CMP with liver enzymes, lactate (mitochondrial function), lactate:pyruvate ratio, CK (muscle damage), CoQ10 (optional). Cardiac indications: BNP or NT-proBNP. Functional: 6-minute walk test, VO2 max, biological age testing. Kidney function: EGFR, creatinine.

Signs to Adjust Protocol Decrease dose or discontinue if: kidney function markers deteriorate, headaches/nausea persist beyond week 1, injection site reactions last >48 hours, or excessive fatigue develops. Increase dose after 2+ weeks if no issues and seeking stronger effect. Split doses >60 units (0.6mL) into two injections or switch to IM route for volumes >1mL.

Drug Interactions and Contraindications Contraindicated in pregnancy, breastfeeding, severe heart/liver/kidney conditions (without supervision), and hypersensitivity to mitochondrial-targeted compounds. Synergistic with NMN (prevents renal oxidative stress). No documented interactions with GLP-1 agonists, though often used together to combat GLP-1 fatigue.

Practical Tips Morning administration aligns with mitochondrial membrane penetration kinetics (peaks within 1 hour). Use 29-31 gauge insulin syringes; 30-unit syringes recommended for accuracy at low doses (500mcg-1mg). Always administer light exposure (sun or red/NIR) post-injection when possible to potentiate biogenesis. Keep detailed logs during 6-month rotation testing to identify individual responder status.

Mechanisms of Action

Cardiolipin Binding and Cristae Stabilization SS-31 penetrates the inner mitochondrial membrane via an alternating cationic-aromatic structure (D-Arg-Dmt-Lys-Phe-NH2), binding cardiolipin through electrostatic and hydrophobic interactions. Cardiolipin possesses four fatty acyl chains (rather than the typical two), creating a cone-like shape and high negative charge necessary for respiratory complex packing. SS-31 stabilizes this architecture, maintaining the tight cristae curvature required for efficient oxidative phosphorylation and preventing cytochrome c release (a cell death signal).

Electron Transport Chain Optimization By stabilizing the cardiolipin-cytochrome c complex, SS-31 prevents electron and proton "slipping" or leak across the electron transport chain. This reduces reactive oxygen species (ROS) generation at the source rather than scavenging radicals after formation. In aged mice (26 months), 8 weeks of 3mg/kg/day treatment restored maximum mitochondrial ATP production (ATPmax) and oxidative phosphorylation coupling efficiency (P/O ratio) to levels approaching young (5-month) controls—without increasing mitochondrial protein expression or respiratory capacity per mitochondrion, indicating functional quality improvement rather than biogenesis.

Redox Homeostasis Restoration SS-31 reverses age-related redox stress by shifting glutathione redox status to a more reduced state and inducing robust reversal of cysteine S-glutathionylation post-translational modifications across the skeletal muscle proteome. This redox optimization correlates with improved mitochondrial function and exercise tolerance independent of mitochondrial proliferation.

Ferroptosis Inhibition In diabetic cardiomyopathy models, SS-31 activates the mitochondrial glutathione/mitoGPX4 pathway and eliminates mitochondrial ferrous ions, alleviating mitochondria-dependent ferroptosis. H9C2 cells exposed to 35mM glucose showed restored ATP generation, improved mitochondrial membrane potential, and restored ultrastructure with SS-31 treatment (10-50µM).

Proposed/Theoretical Mechanisms High-dose SS-31 may theoretically cause "over-spinning" or excessive electron management in the ETC, potentially reversing benefits at extreme doses (analogous to vitamin C's biphasic antioxidant/pro-oxidant effects), though this remains speculative based on practitioner observation rather than controlled data.